Healthcare ETFs Sideline Cannabis Despite Growing Medical Market

Healthcare-focused exchange-traded funds maintain their exclusion of cannabis companies despite the medical marijuana market reaching $30 billion globally. Major ETFs like Vanguard Health Care (VHT) and VanEck Pharmaceutical (PPH) stick to traditional pharmaceutical and biotech holdings while cannabis companies develop FDA-approved medications and expand medical programs across 38 U.S. states.

The disconnect creates a structural investment gap as institutional funds seek healthcare exposure but cannot access cannabis through mainstream ETFs. Medical cannabis companies like GW Pharmaceuticals, now owned by Jazz Pharmaceuticals (JAZZ), proved cannabis-derived drugs can navigate FDA approval processes. However, most cannabis operators remain excluded from healthcare fund mandates due to federal scheduling restrictions.

Traditional pharmaceutical companies increasingly eye cannabis opportunities through partnerships and acquisitions rather than direct cultivation or dispensary operations. This approach allows healthcare ETFs to gain indirect cannabis exposure while maintaining compliance with fund guidelines that typically exclude federally illegal activities.

The exclusion becomes more pronounced as cannabis companies shift focus toward medical applications and pharmaceutical-grade products. Companies developing cannabinoid-based therapeutics often trade at biotech valuations but cannot access biotech-focused institutional capital through ETF channels.

Healthcare ETF managers face pressure to address this gap as medical cannabis legitimacy grows. The sector's evolution toward pharmaceutical standards and potential federal rescheduling could force fund mandate revisions, potentially unlocking billions in institutional healthcare investment currently flowing around cannabis companies despite their medical focus.